Carlton Barnswell, MD
Urology · Elmont, NYNPI 1316921844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,081 of the $107,768 with a category attached, or 78.9%. 46 manufacturers reported payments, led by Johnson & Johnson at 56.5% of the total. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $211.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$61K
- Dendreon Pharmaceuticals LLC$28K
- Astellas Pharma US Inc$7K
- Blue Earth Diagnostics$3K
- Janssen Scientific Affairs, LLC$2K
- Janssen Global Services, LLC$1K
- plus $5K from 40 others
Across 9 payments — averaging $1823.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring Pharmaceuticals AS$10K
- Ferring International Pharmascience Center US$7K
What the payments were for
- Consulting fees$4,8114%
- Speaking & faculty fees$85,08179%
- Travel & lodging$4,6304%
- Food & beverage$12,22511%
- Education$1,0191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,768 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 164 | $2,274,708 |
| ErleadaApalutamide | 122 | $1,780,232 |
| OrgovyxRelugolix | 64 | $172,102 |
| Abiraterone Acetate | 30 | $131,614 |
| EligardLeuprolide Acetate | 88 | $126,855 |
| MyrbetriqMirabegron | 105 | $79,939 |
| XgevaDenosumab | 13 | $41,920 |
| Tamsulosin Hcl | 852 | $12,472 |
| Tadalafil | 134 | $10,766 |
| Tolterodine Tartrate ErTolterodine Tartrate | 86 | $6,831 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $4,709 |
| Trospium Chloride ErTrospium Chloride | 52 | $4,561 |
| Oxybutynin Chloride ErOxybutynin Chloride | 331 | $4,141 |
| Trospium Chloride | 86 | $4,113 |
| Solifenacin Succinate | 55 | $3,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $6,775 | $2,354,646269 claims |
| Johnson & JohnsonErleada | $60,885 | $1,780,232122 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $383 | $172,10264 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,129 | $131,61430 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $164 | $126,85588 claims |
| AmgenXgeva | $95 | $41,92013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in Elmont
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.